Pulmonary hypertension in chronic lung disease and hypoxia.
Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, Olsson KM, Peacock AJ, Pepke-Zaba J, Provencher S, Weissmann N, Seeger W.
Eur Respir J. 2019 Jan 24;53(1):1801914. doi: 10.1183/13993003.01914-2018. Print 2019 Jan.
Pathophysiology of Group 3 Pulmonary Hypertension Associated with Lung Diseases and/or Hypoxia.
Nakamura K, Akagi S, Ejiri K, Taya S, Saito Y, Kuroda K, Takaya Y, Toh N, Nakayama R, Katanosaka Y, Yuasa S.
Int J Mol Sci. 2025 Jan 20;26(2):835. doi: 10.3390/ijms26020835.
Pulmonary hypertension associated with chronic hypoxia: just ASIC-ness?
Aaronson PI.
J Physiol. 2021 Nov;599(21):4731-4732. doi: 10.1113/JP282325. Epub 2021 Sep 30.
Ginsenoside Rg1 ameliorates hypoxia-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition and inflammation by regulating CCN1.
Tang BL, Liu Y, Zhang JL, Lu ML, Wang HX.
Biomed Pharmacother. 2023 Aug;164:114920. doi: 10.1016/j.biopha.2023.114920. Epub 2023 May 20.
Wnt7a deficit is associated with dysfunctional angiogenesis in pulmonary arterial hypertension.
Chakraborty A, Nathan A, Orcholski M, Agarwal S, Shamskhou EA, Auer N, Mitra A, Guardado ES, Swaminathan G, Condon DF, Yu J, McCarra M, Juul NH, Mallory A, Guzman-Hernandez RA, Yuan K, Rojas V, Crossno JT, Yung LM, Yu PB, Spencer T, Winn RA, Frump A, Karoor V, Lahm T, Hedlin H, Fineman JR, Lafyatis R, Knutsen CNF, Alvira CM, Cornfield DN, de Jesus Perez VA.
Eur Respir J. 2023 Jun 8;61(6):2201625. doi: 10.1183/13993003.01625-2022. Print 2023 Jun.
Pathology and pathobiology of pulmonary hypertension: current insights and future directions.
Guignabert C, Aman J, Bonnet S, Dorfmüller P, Olschewski AJ, Pullamsetti S, Rabinovitch M, Schermuly RT, Humbert M, Stenmark KR.
Eur Respir J. 2024 Oct 31;64(4):2401095. doi: 10.1183/13993003.01095-2024. Print 2024 Oct.
Pulmonary hypertension associated with lung diseases and hypoxemia.
Cuttica MJ.
Heart Fail Rev. 2016 May;21(3):299-308. doi: 10.1007/s10741-016-9551-x.
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression.
Born E, Lipskaia L, Breau M, Houssaini A, Beaulieu D, Marcos E, Pierre R, Do Cruzeiro M, Lefevre M, Derumeaux G, Bulavin DV, Delcroix M, Quarck R, Reen V, Gil J, Bernard D, Flaman JM, Adnot S, Abid S.
Circulation. 2023 Feb 21;147(8):650-666. doi: 10.1161/CIRCULATIONAHA.122.058794. Epub 2022 Dec 14.
Mechanisms of hypoxaemia in severe pulmonary hypertension associated with COPD.
Piccari L, Blanco I, Torralba Y, Arismendi E, Gistau C, Ramírez A, Gimeno-Santos E, Roca J, Burgos F, Rodríguez-Roisín R, Barberà JA.
Eur Respir J. 2023 Jul 20;62(1):2300463. doi: 10.1183/13993003.00463-2023. Print 2023 Jul.
Targeting VEGF-A/VEGFR2 Y949 Signaling-Mediated Vascular Permeability Alleviates Hypoxic Pulmonary Hypertension.
Zhou W, Liu K, Zeng L, He J, Gao X, Gu X, Chen X, Jing Li J, Wang M, Wu D, Cai Z, Claesson-Welsh L, Ju R, Wang J, Zhang F, Chen Y.
Circulation. 2022 Dec 13;146(24):1855-1881. doi: 10.1161/CIRCULATIONAHA.122.061900. Epub 2022 Nov 17.
